Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
o2h Ventures investment portfolio
o2h Ventures has made numerous investments in companies such as Turbine Simulated Cell Technologies, Stratosvir, and Kuano within the Biotech sector.
unknown
Portfolio
22
Team
0
Ownership Chain
Sign up free to see the Persons with Significant Control resolved from Companies House.
Sign up freePortfolio (22)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Alevin Therapeutics Limited Alevin Therapeutics is a biotechnology company developing targeted integrin inhibitor medicines for fibrotic diseases, including idiopathic pulmonary fibrosis. | Healthcare & Life Sciences | Cambridge | Confirmed | 2026-03-10 |
| Ascendbio Ltd AscendBio Ltd develops a synthetic‑biology platform that creates curative cell‑therapy medicines, targeting metabolic, gastrointestinal and respiratory diseases in patients. | Healthcare & Life Sciences | Sawston | Confirmed | 2026-02-09 |
Backs Similar Companies
Investors who tend to invest in the same sort of companies.
5 more similar investors hiddenSign up to unlock →
Shareholding changes (19)
O2h Nominees Limited's positions across portfolio companies2026
- B ORDINARY 0 → 8,767
- ORDINARY 0 → 1,289,600
Articles (9)
- Hawkhill Therapeutics secures £1m seed round for obesity treatment9 Sept 2026Hawkhill Therapeutics
- UKI2S takes 11.2% stake in Camgene Therapeutics Limited, RNA therapeutics firm2 Sept 2026Camgene Therapeutics
- Interactive Venture Partners takes 9% stake in Turbine Simulated Cell Technologies23 Aug 2026Turbine Simulated Cell Technologies
- Revolver Therapeutics secures £572k for peptide-based cancer inhibitors24 Jun 2026Revolver Therapeutics
- 11 Jun 2026
- Camgene Therapeutics secures £260k Series A funding for hearing loss treatments19 May 2026Camgene Therapeutics
- 12 May 2026
- Turbine Simulated Cell Technologies raises £22.8m Series B for AI drug discovery platform9 May 2026Turbine Simulated Cell Technologies
- Reo Therapeutics Secures £170k in Early-Stage Funding24 Apr 2026Reo Therapeutics